Background--Left ventricular (LV) hemodynamic assessment has been sparsely performed in patients supported on continuousflow LV assist devices (cfLVADs). Insight into dynamic changes of left heart parameters during ramp studies may improve LV assist device optimization and evaluate pathology.
A n emerging treatment of choice for refractory heart failure (HF), continuous-flow left ventricular (LV) assist devices (cfLVADs) have been implanted in over 15 000 patients as bridge-to-transplant or destination therapy. 1 Continued improvements in outcomes are driven by advancements in surgical technique, miniaturization of devices, anticoagulation and antiplatelet therapies, and management of device thrombosis or malfunction. 2 However, both optimization and evaluation of LV assist device (LVAD) performance pose significant clinical challenges caused by the unique hemodynamic paradigm inherent to continuous-flow devices.
To address this issue, novel strategies have been developed to understand the native heart-cfLVAD interaction. Echocardiography has been combined with incremental increases in LVAD speeds, termed a ramp study, to advance the understanding of continuous-flow hemodynamics. 3 Although ramp studies were originally utilized for diagnosis of LVAD thrombosis, the utility of these tests have been expanded to evaluation and management of LVAD speed optimization and valve disease via echocardiographic parameters. [4] [5] [6] However, echocardiographic ramp studies are hampered by difficulty in consistently obtaining quality echocardiographic images. 4 Furthermore, echocardiographic ramp studies lack resolution for hemodynamic evaluation, 6 which may be exacerbated by differences in devices. 7 These observations fostered the development of the invasive ramp study via right heart catheterization (RHC). Despite genuine advancement, there have been limitations with prior data derived from invasive studies, including small sample sizes, lack of reproducibility, and use of indirect Fick measurements. 6 As such, no invasive ramp study has been able to show correlation between speed adjustments and clinical outcomes. 8 Despite the advances in the understanding of cfLVAD physiology and hemodynamics, real-time evaluation of LV pressures and transaortic hemodynamics have yet to be evaluated under various loading conditions as determined with cfLVAD speed changes. The purpose of the current study is to describe a novel technique for left heart catheterization (LHC) in patients with cfLVADs, establishing a hemodynamic framework whereby LHC findings identify a unique zone of hemodynamics optimization based on the novel transaortic gradient (TAG) and LV end-diastolic pressure (LVEDP). The findings provided with this approach relate to a variety of device support scenarios.
Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Patient Sample
The current study is a retrospective analysis of patients undergoing LHC/RHC ramp study at our institution. Patients included in the current study included those who had previously undergone cfLVAD implantation with a Heartmate II LVAD, Heartmate III LVAD (Abbott Laboratories), or HeartWare ventricular assist device (Medtronic Inc) and who underwent combined RHC and LHC between October 1, 2015, and March 15, 2018 (n=38) . Various indications for LHC were present: 21 (55%) were performed for hemodynamic optimization, 7 (18%) were performed to evaluate aortic insufficiency (AI), 5 (13%) were performed to evaluate for pump thrombosis, 3 (8%) were performed to evaluate for device malfunction or alarms, and 2 (5%) were performed for consideration of weaning of mechanical circulatory support. The Mayo Clinic's institutional review board approved the current study. Requirement for informed consent was waived.
LHC and RHC
Invasive hemodynamic ramp studies were performed on full anticoagulation and antiplatelet therapies, although the recommendation is for an international normalized ratio goal of <3.0 at the time of the procedure. Patients with central coaptation stitch are not suitable for this evaluation as the left ventricle cannot be accessed. Percutaneous arterial access was obtained at the radial artery or brachial artery, both under ultrasound guidance (SonoSite S-ICU, FUJIFILM SonoSite, Inc). An exchange-length wire was bent to establish a 3-cm wide 90-degree bend to prevent accidental entrance into the LVAD inflow cannula upon LV cannulation. A 5F pigtail catheter with the exchange-length wire was brought to the aortic root under fluoroscopic guidance. Once at the aortic valve, the LVAD speed was decreased to allow opening of the aortic valve (as imaged by transthoracic echocardiogram) to facilitate passage into the left ventricle. An exchange-length wire was advanced via the pigtail into the left ventricle. Afterward, the pigtail catheter was removed and a 5F multipurpose guide was advanced over the wire into the left ventricle. The exchange-length wire was removed. A high-fidelity, micromanometer pressure wire (Aeris PressureWire, Abbott Laboratories) was introduced through the guide and placed in the left ventricle, inferior to the inflow cannula. The high-fidelity wire was calibrated to the fluid-filled catheter reading; transducers were zeroed at mid-axilla, measured by laser calipers. The guide catheter was then pulled back into the aorta to generate a simultaneous LV and aortic waveform. The LVAD was typically turned down to 200 to 400 rpm below the baseline speed for the Heartmate II and turned down by 60 to 100 rpm for the HeartWare. From there, increases in speed by 400 rpm (Heartmate II) and 100 rpm (HeartWare) were performed and the transaortic pressure gradient was obtained.
RHC was performed simultaneously. Baseline oxygen consumption was obtained using the Ultima Cpx Metabolic Stress Testing System (MGC Diagnostics C.), for accurate Fick
Clinical Perspective
What Is New?
• Hemodynamics during left heart catheterization ramp study in patients supported on left ventricular (LV) assist device therapy have not been previously reported and results facilitate understanding of LV assist device-native circulation physiology.
• A novel index, the transaortic gradient, helps define LV offloading and correlated inversely with both markers of LV filling pressures and right ventricular systolic function.
What Are the Clinical Implications?
• Left heart catheterization ramp study may be able to further optimize LV assist device speed in patients supported on LV assist device therapy and provides useful data on certain pathologic states (ie, aortic regurgitation and pump thrombosis). 
Device Thrombosis
Our approach to device thrombosis has been previously described. 9 Briefly, device thrombosis is suspected in patients with elevated markers of intravascular hemolysis, defined as greater than twice the baseline value, particularly a lactate dehydrogenase level >1000 U/L, with an elevated plasmafree hemoglobin level (>12 mg/dL) after excluding other causes of hemolysis. Additional necessary findings included either worsening HF or increases in LVAD power by ≥2 W. Confirmed device thrombosis was defined as the presence of thrombosis on the LVAD rotor upon device explant. All patients who met these criteria were admitted and placed on intravenous unfractionated heparin with a goal activated partial thromboplastin time of 50 to 70 seconds or anti-Xa level 0.3 to 0.7 unit/mL and had intensification of their antiplatelet regimen.
Aortic-LV Pressure Gradient (TAG)
A novel index to understand LV-aortic-cfLVAD hemodynamics is the TAG, which was defined as the peak-to-peak gradient between LV systolic pressure and aortic systolic pressure ( Figure S1 ). This is performed with an end-expiratory breath hold to establish a consistent waveform. We attempted to define an optimal range for the TAG to associate with optimal LV hemodynamics and offloading.
Echocardiography
Simultaneous transthoracic echocardiography is performed to evaluate other parameters during the study. At baseline and each subsequent phase, including speed changes or medication changes, LV end-diastolic diameter in diastole, ventricular septal position, mitral regurgitation, qualitative right ventricular (RV) function, AI, and aortic valve opening were evaluated, if possible. AI was graded using techniques endorsed by the American Society of Echocardiography.
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Echocardiography was not only used to optimize patients based on clinical guidelines and assist with the determination of adequate offloading but can be useful to capture suckdown events.
Optimization
At the conclusion of the LHC ramp protocol, we analyzed the TAG in combination with resting biventricular filling pressures and imaging characteristics to define the optimal LVAD speed.
In each case, we attempted to find an LVAD speed that minimized biventricular filling pressures, avoided suck-down events at the inflow cannula, minimized AI if applicable, and maximized Fick-derived cardiac index (CI).
Statistical Analysis
Continuous variables are given as meanAESD unless otherwise stated. Categorical variables are given as number (percentage) unless otherwise stated. Comparison between continuous variables was performed using a Student t test when 2 groups were compared or ANOVA when greater than 2 groups. Sequential values were compared using a matchedpair t test. Categorical variables were compared using Fisher exact test. Linear regression analysis was used to evaluate associations between continuous variables. R 2 values represent the percent variability in the outcome data explained by the independent variable. All data analysis was performed using JMP 13.0 Pro (SAS Institute, Inc).
Results
Patient characteristics are described in the Table. Briefly, the median age of patients was 61 years (interquartile range, 50-66) and most patients were men (24 [63%] ). The device distribution was 20 (53%) Heartmate II, 17 (45%) HeartWare, and 1 (3%) Heartmate III. LHC was performed at a mean of 513AE384 days after implant.
Hemodynamic Optimization
A sample of an LHC hemodynamic tracing is shown in Figure 1 , where a decrease in pulsatility of the LV and aortic waveforms with increasing cfLVAD speed is demonstrated; the TAG rises from 5 mm Hg at baseline to 45 mm Hg at the final speed. The largest cohort of patients (n=21) underwent LHC/RHC to optimize hemodynamics. These patients had an average mean RAP of 13AE5 mm Hg, mean PAP of 28AE9 mm Hg, and mean PCWP of 15AE4 mm Hg. The mean pulmonary vascular resistance of the cohort was 3.1AE2.5 WU. These patients had a mean pulmonary artery pulsatility index of 2.1AE1.0 and an RV stroke work index (RVSWI) of 527AE232 mm Hg9mL/m 2 .
The mean CI was 2.6AE0.7 L/min per m 2 and the mean LVEDP was 13AE6 mm Hg. The mean TAG was 14AE11 mm Hg initially. The mean arterial pressure (centrally measured) was 89AE12 mm Hg at a heart rate of 75AE15 beats per minute. After speed adjustments, the right heart filling pressures were largely unchanged (mean RAP 12AE5 mm Hg, mean PAP 27AE9 mm Hg, and mean PCWP 14AE5 mm Hg). LVEDP was also unchanged (12AE6 mm Hg). There was a rise in the TAG to 20AE13 mm Hg. For patients who required speed adjustments, the patients with a Heartmate II were increased, on average, from 9300 to 9700 rpm and the patients with a HeartWare were increased, on average, from 2620 to 2720 rpm. The single patient with a Heartmate III was increased from 5700 to 5800 rpm.
Evaluation of Hemodynamics
Hemodynamics over the LHC/RHC ramp studies were evaluated to understand biventricular hemodynamics in relation to optimization in the cohort above, as these patients had no suggestion of pathology before the ramp study.
The relationship between parameters of offloading (PCWP, LVEDP, and TAG) and LVAD speeds was evaluated over a clinical range of Heartmate II and HeartWare speeds (Figure 2 Figure 3 shows the relationship between parameters of offloading (LVEDP and PCWP) and TAG as well as parameters of RV function (RV stroke work index and pulmonary artery pulsatility index) and TAG. There were modest yet statistically significant inverse correlations observed between each variable and the TAG. Additionally, while there were significant inverse correlations between CI assessed by direct Fick measurement and PCWP and LVEDP (R 2 =0.11, P=0.003 for both), there was no association between TAG and CI (R 2 =0.0008, P=0.80).
To delineate a reproducible target for optimization, TAG was evaluated against a normalized LVEDP, avoidance of excessive LV "suck-down," RV function, and CI, while operating at a recommended speed. Appropriate offloading, defined as an Establishment of these criteria resulted in reclassification of optimization status. Using previously defined criteria, 38% of the stages evaluated would have met prior optimization criteria (RAP <12 mm Hg and PCWP <16 mm Hg), whereas only 13% of stages met criteria for optimal offloading (20 mm Hg < TAG <40 mm Hg and LVEDP <16 mm Hg), suggesting a narrower band of optimization.
LVAD Thrombosis
Five patients were evaluated for LVAD thrombosis. Each presented with an elevated lactate dehydrogenase level (mean 1070 U/L) and 1 had power spikes just before admission. Baseline hemodynamic parameters were defined for this cohort: mean RAP 11AE7, mean PAP 18AE8 mm Hg, and mean PCWP 15AE8 mm Hg. CI was acceptable, with a mean value of 2.5AE0.4 L/min per m 2 . LVEDP was 12AE5 mm Hg and baseline TAG was 16AE15 mm Hg. Notably, patients had markedly different responses to increasing LVAD speed. As an example, 1 patient had a baseline TAG of 2 mm Hg at 8800 rpm, and the final gradient was 1 mm Hg at 10 000 rpm. The patient continued to have refractory hemolysis despite enhanced anticoagulation and was found to have confirmed device thrombosis upon device exchange. In contrast, the other nonobstructed patients saw a brisk rise in their TAGs to an average of 47 mm Hg at highest achieved speed, suggesting no compromise in pump function from thrombus or obstruction. These findings are shown in Figure 4B .
Aortic Insufficiency
The cohort of patients (n=7) who underwent LHC for AI had elevated filling pressures at baseline speed (mean RAP 15AE7, mean PAP 30AE10 mm Hg, and mean PCWP 18AE7 mm Hg). The resting CI was impaired at 1.9AE0.3 L/min per m 2 . The baseline LVEDP was 17AE3 mm Hg and the TAG was 21AE14 mm Hg. At baseline, guideline-based echocardiographic assessment of AI had been performed. Using these criteria, grades of AI were described as moderate in 5 patients and mild to moderate in 2 patients. Importantly, in most patients, both an increase in TAG and a decrease in LVEDP (down to 17AE4 mm Hg) could be attained ( Figure 4C ). However, in 1 patient with severe exertional symptoms but an echocardiographically determined moderate AI (vena contracta of 4 mm), a rapid increase in LVEDP was noted with modest speed increase despite a lack of change in PCWP, identifying a slower speed as the most optimal setting ( Figure 4C and 4D) . We then evaluated the correlations between PCWP and LVEDP. As expected, in patients being evaluated solely for hemodynamic optimization, we found a strong correlation between PCWP and LVEDP (R 2 =0.45, P<0.0001) ( Figure 5A ).
However, there was no significant association between PCWP and LVEDP in patients undergoing LHC for assessment of AI (R 2 =0.001, P=0.87) ( Figure 5B ).
LVAD Weaning
Two patients underwent unique protocols to examine hemodynamics on decreasing or minimal support for consideration of weaning from permanent mechanical circulatory support. 
Complications of LHC
There are several theoretical complications of LHC in patients with cfLVAD (wire fracture within the inflow cannula with potential for embolization, damage to the aortic valve, aortic perforation or dissection, myocardial infarction, stroke, arterial dissection, or major or minor bleeding). In the current cohort, the only complications observed were minor bleeding following sheath removal in 4 of 38 (11%) patients; however, only 1 of these was related to the arterial sheath (3%), which was a small hematoma.
Echocardiographic Findings
In patients undergoing ramp study for hemodynamic optimization (n=21), the mean pre-LHC LV end-diastolic diameter was 59AE10 mm, but study resulted in a negligible change in mean LV end-diastolic diameter (À0.33 mm, P=0.80). Aortic valve opening was present in 48% (n=10) of the cohort before LHC ramp study, and 2 patients had less aortic valve opening while 1 patient had more aortic valve opening after optimization. The ventricular septum was neutral in 19 of 21 (90%) patients in which it was evaluated, leftward in 2 of 21 (10%) patients, and rightward in 2 of 21 (10%) patients. However, echocardiography only identified one true change in septal position despite relatively large hemodynamic changes across the ramp study.
Discussion
We describe the first series of combined simultaneous RHC and LHC with ramp study in patients supported on cfLVAD therapy. The utility of the TAG and LVEDP, obtained via LHC, is shown and provides significant additive resolution to the data that RHC ramp studies and transthoracic echocardiography provide. To this end, a zone of hemodynamic optimization, termed "Goldilocks zone" was defined herein utilizing LVEDP and TAG. Furthermore, the safety and feasibility of performing LHC catheterization in the LVADsupported population was demonstrated without any significant adverse events.
Hemodynamic Optimization
Hemodynamic optimization continues to be a challenge in the management of patients with cfLVADs. [11] [12] [13] Current data and guidelines support evaluation of numerous end points for optimization, which may be mutually exclusive in certain patients and include normalization of filling pressures, establishment of a neutral septal position, intermittent aortic valve opening, adequate cardiac output, and, most importantly, relief of exertional dyspnea. 14,15 Recent reviews of management of patients with cfLVADs describes not only the difficulty in evaluating the degree of LV offloading but also the difficulty in balancing LV offloading without altering RV geometry to impair filling. 13, 15 However, we believe that simultaneous use of LHC and RHC avoids this difficulty by evaluating biventricular function in relation to LVAD speed, allowing the ability to tune LVAD speed at an optimum setting.
LVAD Physiology and the TAG
Diagrammatic representation of pressure volume loops in the left ventricle under various cfLVAD speeds is provided to therapy by left heart catheterization. Underlying clinical question for which the patients underwent right and left heart catheterization (A) hemodynamic optimization, (B) evaluation of thrombus or obstruction, and (C) evaluation of aortic insufficiency. Highlighted with the red circle in (B) is a patient in whom LVAD thrombosis was diagnosed, resulting in LVAD exchange; there is a clear lack of augmentation of the transaortic gradient (TAG) on speed increase. Highlighted with the green arrow in (C) is a patient with severe aortic insufficiency. The slope of the TAG/LV end-diastolic pressure (LVEDP) line is nearly orthogonal to patients in whom aortic insufficiency was milder. D, Right and left heart catheterization LVAD ramp study with simultaneous monitoring of aortic (Ao; red), LV (grey), right atrial (RA; blue), and pulmonary capillary wedge (PCW; green) pressure waveforms highlight divergence in LVEDP (rise) and pulmonary capillary wedge pressure (PCWP; fall) during LVAD speed increase in a patient with severe aortic insufficiency. VAD indicates ventricular assist device.
highlight the mechanistic basis for TAG changes with a cfLVAD speed ramp ( Figure 6 ). In patients supported on cfLVADs, there is continuous volume removal from the left ventricle throughout the cardiac cycle. As a result, isovolumic relaxation and contraction times are eliminated, creating a triangular shape to the pressure volume loop. As the LVAD speed and flow are increased, a decrease in both preload and afterload of the left ventricle are observed, resulting in a decrement of both the LV stroke work and the peak LV pressure. The end result is the abolishment of pulsatility in the aortic waveform and an increasing dissociation between the aortic pressure and LV pressure as the LVAD device takes on an increasing role of pressurizing the systemic circulation.
TAG likely represents a complex hemodynamics interplay of the left ventricle (offloading, native contractility), as well as the VAD flow; numerically it is the difference between the peak systolic pressure of the aorta and peak systolic pressure of the left ventricle. TAG provides a measurement that is proportional to the pump differential pressure (instantaneous aorticÀLV pressure) and related to LV load. 16 The TAG, therefore, represents a more reliable marker of true LVAD offloading, and a low TAG at baseline may identify inadequate LV unloading by the cfLVAD independently of LVEDP or PCWP findings. Furthermore, TAG is noted to be much better associated with speed changes, suggesting it is the most sensitive parameter to assess offloading. In the majority of patients, an increase in LVAD rpm results in an increase in TAG and a decrease in LVEDP (Figures 2 and 4A) . Separately, an inability to augment the TAG with speed ramp may signal a dysfunctional LVAD circuit (eg, rotor thrombus, cannula thrombus, severe kinking, and LVAD malfunction), providing a more definitive assessment upon which to decide about necessity of exchange. While a decrement in TAG could occur over time as a result of increased native cardiac contractility due to reverse remodeling, the presence of an elevated LVEDP ( Figure 3 ) in tandem with symptomatic HF would suggest inadequate unloading. However, the effect of unloading of the left ventricle via increasing pump speed may have various effects on the right ventricle. [17] [18] [19] [20] While increased LV unloading results in reduced PCWP and decreasing pulmonary circulation resistance, it may have deleterious effects on RV function. First, negative pressure within the LV cavity in systole may induce a conformational change in the right ventricle that may impair septal contribution to RV systolic function. Second, increased LVAD flow may result in volume loading of the right ventricle, which has been shown to exhibit impaired adaptation to load over time in patients supported on LVAD therapy. 21 In our experience, a TAG between 20 and 40 mm Hg and an LVEDP <16 mm Hg, results in optimal hemodynamics in the catheterization laboratory. Theoretically, the optimal TAG should be associated with the greatest CI as LVAD flows are generally higher with greater LVAD speeds until increasing afterload diminishes flow, as suggested by H-Q curves, 16, 22 or the RV cannot accommodate increased load. Nevertheless, clinical outcomes related to achieving this threshold have yet to be ascertained and should be a focus of ongoing work. Previously, however, improvements in hemodynamics as a result of ramp studies were associated with improved quality of life and functional capacity. 23 
Simultaneous Transthoracic Echocardiography
We were unable to determine any specific echocardiographic markers that corresponded well with the hemodynamic pressure waveform tracings observed in the acute setting. Ventricular septal position was relatively insensitive for even significant changes in LV offloading. Echocardiography provided valuable data about aortic valve opening, mitral regurgitation, suck-down, and LV dimensions and provides a resource to monitor the long-term structural impact of hemodynamic optimization.
Clinical Utility and Role for LHC During LVAD Ramp Studies
Our preliminary results are insufficient to determine the precise role for the LHC ramp study in the routine evaluation of a patient with an LVAD. However, we believe that these data create a foundation on which to build an understanding of LV hemodynamics in patients supported with LVAD therapy, both for optimization and pathologic states. Specific areas of potential research interest going forward include:
1. Initial LVAD optimization postimplant. 2. Evaluating the extent of aortic regurgitation when guidelines and potential novel noninvasive indices are insufficient. 4, 23 3. Evaluating pump thrombosis when the intensive antiplatelet and anticoagulation regimen has not improved markers of hemolysis and clinical concern persists. 4. Evaluating patients for weaning from permanent mechanical support. 24 
Limitations
The present study is a retrospective analysis of a cohort of patients undergoing complex hemodynamic RHC and LHC at our institution for thorough evaluation of hemodynamics, which may result in a sampling bias. Patients with coagulopathies, sutured aortic valves, or lost to follow-up may be among those who did not undergo an LHC. The purpose of this study was to illustrate safety, feasibility, and utilization of this novel technique and to describe a systematic way in which it can be applied. Definitive conclusions cannot be drawn from the hemodynamic values obtained here, and the results shown are purely hypothesis-generating. However, this work creates a framework by which to derive future knowledge on hemodynamics in patients supported on cfLVADs and does provide initial evidence for utility in the evaluation and diagnosis of patients supported by durable continuous-flow devices. Additionally, the hemodynamics in the current study were not acquired in a blinded fashion per se but these are objective data and the initial clinical protocols were refined over the course of the study. Last, the hemodynamics including afterload were not actively manipulated during the study with volume or medications, limiting our observations to the impact of LVAD RPM. Beyond TAG and LVAD RPM assessment, future studies that manipulate preload, LV filling pressure, LV afterload, and RV afterload as key mediators of LVAD hemodynamics are warranted.
Conclusions
A novel technique for the hemodynamic evaluation of patients supported on durable cfLVADs is described. While the invasive nature of the diagnostic study precludes universal application in this cohort of patients, there may be specific indications for utilization of LHC in patients with cfLVADs, providing incremental data to assist the HF clinician with critical decisionmaking in selected scenarios. Future research should focus on the evaluation of LHC hemodynamics in a standardized way to establish thresholds useful to the advanced HF clinician.
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